ELEKTA logoElekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EKTAY
  • CUSIP: N/A
  • Web: www.elekta.com
Average Prices:
  • 52 Week Range: $7.97 - $11.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 28.67
  • P/E Growth: 0.00
  • Dividend Yield: 1.1%

Frequently Asked Questions for ELEKTA (NASDAQ:EKTAY)

What is ELEKTA's stock symbol?

ELEKTA trades on the NASDAQ under the ticker symbol "EKTAY."

How often does ELEKTA pay dividends? What is the dividend yield for ELEKTA?

ELEKTA announced a None dividend on Thursday, July 20th. Investors of record on Friday, August 25th will be paid a dividend of $0.04 per share on Thursday, September 14th. The ex-dividend date of this dividend is Wednesday, August 23rd. View ELEKTA's Dividend History.

How were ELEKTA's earnings last quarter?

ELEKTA (NASDAQ:EKTAY) announced its quarterly earnings results on Wednesday, December, 4th. The company reported $0.07 earnings per share (EPS) for the quarter. View ELEKTA's Earnings History.

When will ELEKTA make its next earnings announcement?

ELEKTA is scheduled to release their next quarterly earnings announcement on Thursday, September, 28th 2017. View Earnings Estimates for ELEKTA.

Who are some of ELEKTA's key competitors?

How do I buy ELEKTA stock?

Shares of ELEKTA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ELEKTA's stock price today?

One share of ELEKTA stock can currently be purchased for approximately $11.18.

MarketBeat Community Rating for ELEKTA (NASDAQ EKTAY)
Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about ELEKTA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ELEKTA (NASDAQ:EKTAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A

Analysts' Ratings History for ELEKTA (NASDAQ:EKTAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/7/2016Jefferies Group LLCDowngradeHold -> UnderperformN/AView Rating Details
12/8/2015Morgan StanleyDowngradeEqual Weight -> UnderweightN/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for ELEKTA (NASDAQ:EKTAY)
Earnings by Quarter for ELEKTA (NASDAQ:EKTAY)
Earnings History by Quarter for ELEKTA (NASDAQ EKTAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q4$0.02$295.66 millionViewListenView Earnings Details
12/4/2013Q3$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ELEKTA (NASDAQ:EKTAY)
Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.39 EPS


Dividend History by Quarter for ELEKTA (NASDAQ EKTAY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for ELEKTA (NASDAQ:EKTAY)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for ELEKTA (NASDAQ:EKTAY)
Latest Headlines for ELEKTA (NASDAQ:EKTAY)
finance.yahoo.com logoElekta and IBA Enter an MOU Regarding a Comprehensive Partnership Including Joint Software Development and Sales to Advance Proton Therapy Treatments
finance.yahoo.com - September 23 at 5:53 PM
finance.yahoo.com logoElekta and Brainlab Collaborate to Streamline Treatment Workflows for Stereotactic Radiation Therapy
finance.yahoo.com - September 22 at 5:18 PM
finance.yahoo.com logoElekta to Highlight MOSAIQ Oncology Analytics, a Game-changing Solution for Managing the Oncology Treatment Pathway, at ASTRO Annual Meeting
finance.yahoo.com - September 18 at 6:03 PM
finance.yahoo.com logoBulovka Hospital First in Czech Republic to Offer Advanced Cancer Treatment Using Elekta Versa HD
finance.yahoo.com - September 13 at 5:04 AM
finance.yahoo.com logoGenesis CancerCare Queensland is First in Asia-Pacific Region to use Elekta's Venezia Brachytherapy Applicator
finance.yahoo.com - September 11 at 3:36 AM
finance.yahoo.com logoElekta repeats margin target as Q1 core profit lags expectations
finance.yahoo.com - August 23 at 4:49 AM
americanbankingnews.com logo ELEKTA (EKTAY) Given Average Rating of "Sell" by Analysts
www.americanbankingnews.com - August 8 at 10:18 PM
seekingalpha.com logoAccuray Looks Undervalued, But A Lack Of Execution Is A Longstanding Problem
seekingalpha.com - August 8 at 5:56 PM
finance.yahoo.com logoUniversity Hospitals Seidman Cancer Center Launches Use of Elekta's Venezia Gynecological Applicator for Patients With Advanced Cervical Cancer
finance.yahoo.com - August 8 at 5:56 PM
americanbankingnews.com logoZacks Investment Research Upgrades ELEKTA (NASDAQ:EKTAY) to Hold
www.americanbankingnews.com - August 7 at 7:30 PM
finance.yahoo.com logoElekta AB :EKTAY-US: Earnings Analysis: Q4, 2017 By the Numbers : August 4, 2017
finance.yahoo.com - August 4 at 6:30 PM
finance.yahoo.com logoElekta to Highlight High Definition Dynamic Radiosurgery with Versa HD and Monaco at AAPM Annual Meeting
finance.yahoo.com - July 28 at 8:14 PM
finance.yahoo.com logoElekta's MR-linac Featured in 21 Abstracts at 2017 AAPM Annual Meeting
finance.yahoo.com - July 28 at 8:14 PM
americanbankingnews.com logoZacks: ELEKTA (EKTAY) Given Average Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - July 24 at 10:10 AM
finance.yahoo.com logoElekta Introduces Advanced Cancer Treatment to Kingdom of Bhutan
finance.yahoo.com - July 24 at 10:08 AM
americanbankingnews.com logoELEKTA to Issue None Dividend of $0.04 (NASDAQ:EKTAY)
www.americanbankingnews.com - July 21 at 11:52 AM
seekingalpha.com logoViewRay: Initiate Strong Sell On Questionable Backlog, Product Inferiority, And Bankruptcy Concerns
seekingalpha.com - July 20 at 3:35 PM
americanbankingnews.com logoZacks: ELEKTA (NASDAQ:EKTAY) Receives Average Recommendation of "Sell" from Analysts
www.americanbankingnews.com - July 19 at 6:30 PM
seekingalpha.com logoViewRay Expands Across The World
seekingalpha.com - July 6 at 7:24 PM
finance.yahoo.com logoParkinson's Disease Patients are First to be Treated With Elekta's New Leksell Vantage Stereotactic System
finance.yahoo.com - June 28 at 3:11 AM
finance.yahoo.com logoIsala and Elekta Sign Long-term Partnership Agreement for Optimal Cancer Care
finance.yahoo.com - June 27 at 5:11 PM
finance.yahoo.com logoElekta Chooses Brainlab to Distribute Stereotactic Neurosurgical Solutions Within Selected Markets in Europe
finance.yahoo.com - June 26 at 5:54 PM
finance.yahoo.com logoFirst Patient in Canada Treated with Elekta's Leksell Gamma Knife Icon
finance.yahoo.com - June 22 at 10:08 AM
americanbankingnews.com logo ELEKTA (EKTAY) Given Consensus Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - June 21 at 4:38 PM
finance.yahoo.com logoAlliance Cancer Care to Upgrade Cancer Care in Southeastern U.S. with Elekta Solutions
finance.yahoo.com - June 20 at 5:37 PM
finance.yahoo.com logoNew Data From the Elekta Lung Research Group Support the use of Stereotactic Body Radiation Therapy in Elderly Patients With Early-stage Lung Cancer
finance.yahoo.com - June 15 at 7:01 PM
americanbankingnews.com logoELEKTA (EKTAY) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - June 6 at 6:54 PM
finance.yahoo.com logoElekta shares fall after big Q4 earnings miss
finance.yahoo.com - June 1 at 5:38 PM
finance.yahoo.com logoElekta Radiosurgery Solutions Highlighted at International Stereotactic Radiosurgery Society Congress
finance.yahoo.com - May 26 at 5:33 PM
finance.yahoo.com logoElekta Unity, Transformative Magnetic Resonance Radiation Therapy (MR/RT) System, Debuts at ESTRO 36
finance.yahoo.com - May 6 at 10:44 AM
americanbankingnews.com logoZacks: ELEKTA (EKTAY) Receives Consensus Rating of "Sell" from Analysts
www.americanbankingnews.com - May 4 at 11:04 PM
americanbankingnews.com logoELEKTA (EKTAY) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 2 at 9:38 PM
finance.yahoo.com logoElekta to Showcase the Latest in Stereotactic Solutions at ESTRO 36
finance.yahoo.com - May 2 at 3:57 PM
finance.yahoo.com logoPatient in Germany is World's First to Receive Brachytherapy With Elekta's New Venezia Gynecological Applicator
finance.yahoo.com - April 26 at 11:29 PM
finance.yahoo.com logoElekta to Highlight Continued Innovation in Stereotactic Neurosurgery with Leksell Vantage Stereotactic System at AANS
finance.yahoo.com - April 24 at 4:48 PM
americanbankingnews.com logoZacks: ELEKTA (EKTAY) Receives Consensus Recommendation of "Sell" from Brokerages
www.americanbankingnews.com - April 17 at 6:18 PM
americanbankingnews.com logo ELEKTA (EKTAY) Receives Consensus Recommendation of "" from Brokerages
www.americanbankingnews.com - March 29 at 12:02 PM



ELEKTA (EKTAY) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff